Observational studyAIDS (London, England)2025
The cumulative prevalence of HIV-1 drug resistance in perinatal HIV.
Observational study in AIDS (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Risk factors associated with adverse metabolic health in youth with perinatally acquired HIV living in the United Kingdom.AIDS (London, England) · 2026Observational
- Age and viral replication, not vertical HIV acquisition, drive inflammation and T-cell dysfunction in heavily treatment experienced: data from the Prestigio Registry.AIDS (London, England) · 2026Article
- Sexual and reproductive health issues facing young people with perinatal HIV infection.AIDS (London, England) · 2025Article
- Aging of adult lifetime survivors with perinatal HIV.Current opinion in HIV and AIDS · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo describe acquired drug resistance mutations (DRMs) among children and adults with perinatal HIV stratified by age.
designA retrospective observational cohort study.
methodsData on demographics, antiretroviral therapy (ART), viral load, CD4 + cell count, and lifetime cumulative acquired DRMs was collected and disaggregated by birth era; pre and post 2000; 0-24 and at least 25 years ( n = 113 vs. 167).
resultsTwo hundred eighty individuals (median age 26 years, interquartile range 21-30), 235 (84%) Black ethnicity, 160 (57%) female, with median ART exposure 17 years. About 99.6% currently on ART, 205 (73%) integrase strand transfer inhibitor (INSTI) regimens, with 252 (90%) viral load less than 200 copies/ml. One hundred twenty-one of 280 (43%) acquired resistance to at least one ART class (37% 0-24 vs. 47% ≥ 25 years), 69/280 (25%) at least two (14 vs. 32%), and 13/280 (4.6%) at least three class; 11/13 (85%) aged at least 25 years. DRMs by ART class; 104/280 (37%), nonnucleoside reverse transcriptase inhibitor (NNRTI), 78 (28%) nucleoside reverse transcriptase inhibitor (NRTI), 15 (5%) protease inhibitor, and 4 (1%) INSTI. Uni/multivariate analysis; DRM acquisition was significantly associated with more than two anchor class exposure ( P = 0.000), prior AIDS diagnosis ( P = 0.001, 0.085), and early mono/dual NRTI exposure ( P = 0.000, 0.029).
conclusionDespite improved ART efficacy, DRMs limit treatment options, including long-acting injectable therapies with one-third having NNRTI-DRMs. Outcomes for second-generation INSTIs are promising with low rates of resistance but require continued monitoring. While multidrug resistance rates are lower in those born post2000, over one-third already have DRMs, highlighting the ongoing need for patient-centered approaches addressing adherence and novel ART class development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.